Xaira Therapeutics, a San Francisco-based AI biotech firm, launched with over $1 Billion in funding.

Key backers include ARCH Venture Partners, Foresite Capital, NEA, Sequoia Capital, and more. The funds will drive product development and AI research.

Led by CEO Dr. Marc Tessier-Lavigne, the company's strategy merges AI with biological data to innovate drug discovery.

Co-founded by Dr. David Baker and supported by an experienced executive team, Xaira aims to revolutionize medicine through advanced AI applications.